HK Stock Market Move | INSILICO (03696) rose more than 7% again, breaking through the peak, the company's AI-enabled tumor drug research and development capabilities are once again recognized.

INSILICO (03696) rose by over 7%, reaching a new high of 61.3 Hong Kong dollars. As of the time of writing, it has risen by 2.02% to 58.15 Hong Kong dollars, with a total turnover of 48.29 million Hong Kong dollars. In terms of news, INSILICO recently reached a long-term research and development cooperation with Shweyadar to develop anti-tumor drugs using the AI platform Pharma.AI. China Post Securities released a research report stating that INSILICO has rich experience in AI-driven tumor drug research and has established a pipeline covering multiple cancer indications. The pan-TEAD inhibitor ISM6331 and the MAT2A inhibitor ISM3412 have already initiated global multicenter Phase I clinical trials, with four other tumor projects already licensed externally. Guotou Securities International stated that INSILICO has a luxurious lineup of cornerstone investors and is in a leading position in the field of AI drug discovery. The company's self-developed generative artificial intelligence platform Pharma.AI has incubated over 20 assets in clinical or IND filing stages, three of which have been licensed to international pharmaceutical companies with a total contract value of up to 2.1 billion US dollars, as well as a Phase II asset in the self-development stage.